Study type: Human research · Status: Verified against declared source

The impact of cathelicidin, the human antimicrobial chemical sequence LL-37 in urinary tract infections.

BMC infectious diseases · 2018

Study scale: This is a case-control study was conducted at Omdurman Hospital, Sudan, during the period June–September 2014.

Abstract only: Open source record

Product or molecular entity relationships

LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

A case-control study was conducted at Omdurman Hospital, Sudan during the period from August 2014 to May 2017.

Methods

The bacterial identification and the antimicrobial susceptibility were done by using the fully automated VITEK-2 Compact System.

Scale or participants

This is a case-control study was conducted at Omdurman Hospital, Sudan, during the period June–September 2014.

Key findings

Cases and controls (87 in each arm) were matched according to their basic characteristics.

Limitations and uncertainty

Production of cathelicidin peptides by blood cells [4] and by the epithelial cells in the urothelium mucous membranes has been proposed as a natural innate immune response to maintain a normal sterile urinary tract and represents a candidate for a novel class of antimicrobials [25, 26].

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.